Company Profile
Terns Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- TERN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
52.95 USD (+0.04%)
Close
Last updated: May 4, 2026
6.12B USD
Market cap
Why the stock is moving
Current closing-price context is not available for TERN.
Company overview
Business overview
Terns Pharmaceuticals is a small-molecule biotech focused on oncology and metabolic disease opportunities. Its pipeline is built around targeted therapies with room for multiple shots on goal.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Terns sits in specialty biotechnology.
Business Model Characteristics
The company depends on clinical proof-of-concept, dose selection, and whether its pipeline can generate differentiated value.
Position Within the Biotechnology Landscape
Terns is a high-beta development name whose stock reacts quickly to early clinical and strategic updates.
Future catalysts
Terns Pharmaceuticals's catalysts are TERN-601 in obesity and TERN-701 in CML, the two programs that most directly determine whether the company has a real differentiated future. The market will care about whether either asset can keep the story moving.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Terns Pharmaceuticals (TERN)?
Terns Pharmaceuticals (TERN) most recently closed at 52.95 USD, a +0.04% move versus the previous session.
What is the market cap of Terns Pharmaceuticals (TERN)?
Terns Pharmaceuticals currently has a market capitalization of 6.12B USD on BioPharmSignal.
What does Terns Pharmaceuticals do?
Terns Pharmaceuticals is a small-molecule biotech focused on oncology and metabolic disease opportunities. Its pipeline is built around targeted therapies with room for multiple shots on goal.
On which exchange is TERN stock listed?
Terns Pharmaceuticals (TERN) is associated with NASDAQ, United States, Biopharma.
What is TERN-601?
Terns Pharmaceuticals's catalysts are TERN-601 in obesity and TERN-701 in CML, the two programs that most directly determine whether the company has a real differentiated future.
Which conditions is Terns Pharmaceuticals targeting with TERN-601?
Terns Pharmaceuticals is associated with oncology, metabolic disease, obesity based on its company overview and current catalyst commentary.
How does Terns Pharmaceuticals describe recent progress with TERN-601?
Terns Pharmaceuticals's catalysts are TERN-601 in obesity and TERN-701 in CML, the two programs that most directly determine whether the company has a real differentiated future.
What is TERN-701?
Terns Pharmaceuticals's catalysts are TERN-601 in obesity and TERN-701 in CML, the two programs that most directly determine whether the company has a real differentiated future.